Cargando…

Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture

Acute Epstein-Barr virus (EBV) infection in immunosuppressed transplant patients can give rise to a malignant B-cell proliferation known as post-transplant lymphoproliferative disease (PTLD). The EBV major virion surface glycoprotein (gp)350 is a principal target of naturally occurring neutralizing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanner, Jerome E., Hu, Jing, Alfieri, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923367/ https://www.ncbi.nlm.nih.gov/pubmed/29642526 http://dx.doi.org/10.3390/cancers10040112

Ejemplares similares

Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
por: Liu, Hui, et al.
Publicado: (2020)

Epitope mapping of gp350/220 conserved domain of epstein barr virus to develop nasopharyngeal carcinoma (npc) vaccine
por: Sitompul, Loly Sabrina, et al.
Publicado: (2012)

Immunization With Fc-Based Recombinant Epstein–Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model
por: Zhao, Bingchun, et al.
Publicado: (2018)

Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350
por: Mok, Hoyin, et al.
Publicado: (2012)

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
por: Slabik, Constanze, et al.
Publicado: (2020)

A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits
por: Escalante, Gabriela M., et al.
Publicado: (2020)

A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus
por: Zhong, Ling, et al.
Publicado: (2022)

Epstein-Barr Virus Antibodies in Kawasaki Disease
por: Lee, Soon-Ju, et al.
Publicado: (2006)

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
por: Zhu, Qian-Ying, et al.
Publicado: (2020)

The Epstein-Barr Virus
por: Payne, L. N.
Publicado: (1980)

A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus
por: Zhu, Qian-Ying, et al.
Publicado: (2021)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice
por: Ogembo, Javier Gordon, et al.
Publicado: (2015)

Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome
por: Taheraghdam, Aliakbar, et al.
Publicado: (2014)

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells
por: Gram, Anna M., et al.
Publicado: (2016)

HLA-DPB1 and Epstein-Barr virus gp42 protein jointly contribute to the development of Hodgkin lymphoma
por: Li, Hongyu, et al.
Publicado: (2020)

Epstein - Barr virus Pneumonitis
por: McManus, Terence E, et al.
Publicado: (2009)

Epstein–Barr virus vaccines
por: Cohen, Jeffrey I
Publicado: (2015)

Epstein–barr virus vaccines
por: Cohen, Jeffrey I
Publicado: (2015)

Epstein-Barr virus and skin
por: Sangueza-Acosta, Martin, et al.
Publicado: (2018)

Epstein-Barr Virus Gastritis
por: Oki, Masayuki, et al.
Publicado: (2017)

Resurrecting Epstein–Barr Virus
por: Paganelli, Roberto
Publicado: (2022)

Characterization of an Epstein-Barr virus receptor on human epithelial cells
Publicado: (1992)

Evolution of functional antibodies following acute Epstein-Barr virus infection
por: Karsten, Christina B., et al.
Publicado: (2022)

Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma
por: Coghill, Anna E, et al.
Publicado: (2022)

Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases
por: Wongwiwat, Wiyada, et al.
Publicado: (2022)

Epstein‐Barr Virus‐related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti‐CD30
por: Montes, Lydia, et al.
Publicado: (2020)

Epstein-Barr Virus and Human Cancer
por: Young, Lawrence
Publicado: (2002)

An Epstein-Barr virus-associated superantigen
Publicado: (1996)

Macular Amyloidosis and Epstein-Barr Virus
por: Nahidi, Yalda, et al.
Publicado: (2016)

Epstein-Barr virus infection mechanisms
por: Chesnokova, Liudmila S., et al.
Publicado: (2014)

Epstein-Barr Virus Neurologic Complications
por: Millichap, J. Gordon
Publicado: (2015)

Epstein–Barr virus latent genes
por: Kang, Myung-Soo, et al.
Publicado: (2015)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

Epstein-Barr virus and Burkitt lymphoma
por: Rowe, Martin, et al.
Publicado: (2014)

Epstein-Barr Virus in Gastric Carcinoma
por: Nishikawa, Jun, et al.
Publicado: (2014)

Epstein–Barr Virus and Hemophagocytic Lymphohistiocytosis
por: Marsh, Rebecca A.
Publicado: (2018)

The Epstein Barr virus circRNAome
por: Ungerleider, Nathan, et al.
Publicado: (2018)

Novel Therapeutics for Epstein–Barr Virus
por: Andrei, Graciela, et al.
Publicado: (2019)

Epstein–Barr virus-associated lymphomas
por: Shannon-Lowe, Claire, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5il3fv9stf785ti5tua50o0486